Description

ELORALINTIDE Next-generation, receptor-selective amylin agonist being studied for appetite control, early satiety, and weight management. Potential Benefits Strong appetite suppression Promotes early satiety Potential fat-mass reduction Potential lean-mass preservation Improved GI tolerability through reduced CTR activation Being studied as a potential Tirzepatide combination partner Research Highlight: Phase 2 research reported 20.1% mean weight loss at 48 weeks, with approximately 85% of weight loss from fat mass. ⚠️ MEDICAL DISCLAIMER: Eloralintide is an investigational compound and is not FDA-approved for human use. Information provided is for educational/research purposes only and is not medical advice. No official research-grade powder reconstitution guidance has been published. For research use only. Not for human consumption.